Noah Berkowitz - 11 May 2026 Form 4 Insider Report for ARVINAS, INC. (ARVN)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
13 May 2026, 16:16:06 UTC
Prior SEC filing
19 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jared Freedberg, as attorney-in-fact for Noah Berkowitz

Key filing fact

Noah Berkowitz filed Form 4 for ARVINAS, INC. (ARVN) on 13 May 2026.

Key facts

  • This page summarizes Noah Berkowitz's Form 4 filing for ARVINAS, INC. (ARVN).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 13 May 2026, 16:16.

Change

  • Previous filing in this sequence was filed on 19 Mar 2026.
  • Current net transaction value: -$110,385.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001369900 Primary reporting owner

Berkowitz Noah

Relationship
Chief Medical Officer
Address
C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN
Signature
/s/ Jared Freedberg, as attorney-in-fact for Noah Berkowitz
Signature date
13 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARVN transaction

Common Stock

Sale

Transaction value
$110,385
Shares
-11,108
Change %
-5.5%
Price
$9.94
Shares after
191,395
Date
11 May 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .